Studies have found that upregulation of miR-425-5p sensitizes human PCa to cisplatin by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway, providing a new target for treating PCa, particularly cisplatin-resistant PCa [128]. The gene discussed is GSK3B; the disease is posterior cortical atrophy.